Please login to the form below
Woodford
This page shows the latest Woodford news and features for those working in and with pharma, biotech and healthcare.
ReNeuron set for recovery after Woodford stake sale
Edison analyst says sale should help shares to stabilise. Shares in UK biotech ReNeuron have been depressed in recent months thanks to a sizeable holding held by the now-defunct Woodford ... That’s the view of Edison analyst John Savin, who reckons the
Latest news
-
UK biotech funding falls 40% between 2018 and 2019
Drop attributed to global uncertainty and Neil Woodford scandal. After a record-breaking year for UK biotech in 2018, the UK BioIndustry Association has revealed overall investment fell to £1.3bn ... According to Dan Mahony, partner at Polar Capital,
-
Bayer taps Sensyne Health AI and real world data for cardiovascular research
It also has financial backing from Woodford Investment Management and Landsdowne Partners.
-
UK financial authority confirms Woodford probe
The FCA confirms the investigation is ongoing but won’t comment any further, and Woodford has said he will be cooperating fully with the probe. ... Shares in Woodford’s FTSE 250-listed vehicle, Patient Capital Trust, are now trading at just over
-
AI company Sensyne raises £60m in IPO
Oxford-based Sensyne is led by former UK science minister Paul Drayson and unusually features three NHS Trusts among its shareholders, along with significant backing from Woodford Investment Management and Landsdowne
-
Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD
The company’s top brass has rejected such a move in recent years – ex-CEO Andrew Witty resisted the idea, even when high profile investor Neil Woodford sold his stake in
More from news
Approximately 3 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Building European biotech firms to rival those of the US
Neil Woodford’s problems haven’t damaged UK biotech. Neil Woodford had been a star UK fund manager over the last decade, and his views and investments in big pharma and ... Neil Woodford has done a huge amount for the life sciences industry in the UK,
-
European venture funding for the life science sector
BenevolentAI, rumoured to enjoy a ‘unicorn’ valuation, has Woodford and Landsdowne as major investors.
-
Pharma deals in July 2015
including Woodford Investment Management (a UK investment fund) and Eli Lilly. ... Woodford has also been an investor in the deal whereby Novartis spun off three phase II products for an equity stake in a newly formed company, Mereo Biopharma, which
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Ameco Research
Address:. Unit1, 26 Cleveland Road, South Woodford. London. E182AN. United Kingdom.
-
Global QYResearch
Address:. Unit 1, 26 Cleveland Road. South Woodford , London. London.
-
Create Health
View LinkedIn profile. Joel Woodford. Designer. View LinkedIn profile. Jasmine Freeman.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
